Comparative Transcriptomic Analysis of Human Macrophages During <i>Mycobacterium avium</i> Versus <i>Mycobacterium tuberculosis</i> Infection
The treatment of Mycobacterium avium (Mav) infection, responsible for over 80% of nontuberculous mycobacterial pulmonary disease, remains challenging due to rising antibiotic resistance and unsatisfactory success rates. Hence, there is a need for a deeper understanding of host-pathogen interactions to inform the development of alternative therapeutic approaches, like host-directed therapy (HDT), aimed at improving host antimycobacterial defenses. However, compared to Mycobacterium tuberculosis (Mtb) infections, knowledge of host-pathogen interactions for Mav infection is still limited. To address this knowledge gap, we performed a genome-wide host transcriptomic analysis of Mav-infected primary human macrophages-the primary host cell-alongside Mtb-infected macrophages to leverage insights from Mtb research. Our findings show substantial overlap in the gene expression patterns between Mav-infected and Mtb-infected macrophages, including induction of cytokine responses and modulation of various G-protein coupled receptors (GPCRs) involved in (lipid-mediated) macrophage immune functions. Notable differences were observed in the expression of immediate early genes (IEGs), phospholipases, and genes of the GTPase of immunity-associated protein (GIMAP) family. This study laid a foundation for identifying both shared and Mav-specific host response pathways, providing direction for future investigations into host-pathogen interactions during Mav infection and the identification of novel targets for HDT.
Authors
- Gül Kilinç (ORCID: https://orcid.org/0000-0003-3521-3842)
- A. Jamie Saris
- R J M van den Biggelaar
- Leon H. Mei
- Tom H. M. Ottenhoff
Institutions
- Leiden University Medical Center (NL)
Publication Details
- Journal
- Molecular Microbiology
- Published
- 2026-01-05
- DOI
- https://doi.org/10.1111/mmi.70045
- Primary Topic
- Tuberculosis Research and Epidemiology
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- European Federation of Pharmaceutical Industries and Associations
- European Commission
- Nederlandse Organisatie voor Wetenschappelijk Onderzoek